These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 37189643)

  • 1. Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Strategies and Biomarkers Predicting Response and/or Resistance.
    Pelizzaro F; Farinati F; Trevisani F
    Biomedicines; 2023 Mar; 11(4):. PubMed ID: 37189643
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination immunotherapy for hepatocellular carcinoma.
    Rimassa L; Finn RS; Sangro B
    J Hepatol; 2023 Aug; 79(2):506-515. PubMed ID: 36933770
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact and Novel Perspective of Immune Checkpoint Inhibitors in Patients with Early and Intermediate Stage HCC.
    Marzi L; Mega A; Gitto S; Pelizzaro F; Seeber A; Spizzo G
    Cancers (Basel); 2022 Jul; 14(14):. PubMed ID: 35884392
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biochemical predictors of response to immune checkpoint inhibitors in unresectable hepatocellular carcinoma.
    Rizzo A; Brandi G
    Cancer Treat Res Commun; 2021; 27():100328. PubMed ID: 33549983
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy for hepatocellular carcinoma.
    Childs A; Aidoo-Micah G; Maini MK; Meyer T
    JHEP Rep; 2024 Oct; 6(10):101130. PubMed ID: 39308986
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
    Xing R; Gao J; Cui Q; Wang Q
    Front Immunol; 2021; 12():783236. PubMed ID: 34899747
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of immunotherapy in hepatocellular carcinoma: Does liver disease etiology have a role?
    Pinto E; Meneghel P; Farinati F; Russo FP; Pelizzaro F; Gambato M
    Dig Liver Dis; 2024 Apr; 56(4):579-588. PubMed ID: 37758610
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trial watch: immunotherapeutic strategies on the horizon for hepatocellular carcinoma.
    Koh B; Tan DJH; Lim WH; Wong JSL; Ng CH; Chan KE; Wang M; Yong WP; Dan YY; Wang LZ; Tan N; Muthiah M; Kow A; Syn NL; Huang DQ; Yau T
    Oncoimmunology; 2023; 12(1):2214478. PubMed ID: 37284696
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The liver cancer immune microenvironment: Therapeutic implications for hepatocellular carcinoma.
    Donne R; Lujambio A
    Hepatology; 2023 May; 77(5):1773-1796. PubMed ID: 35989535
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapy with Checkpoint Inhibitors for Hepatocellular Carcinoma: Where Are We Now?
    Tovoli F; De Lorenzo S; Trevisani F
    Vaccines (Basel); 2020 Oct; 8(4):. PubMed ID: 33023131
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advanced development of biomarkers for immunotherapy in hepatocellular carcinoma.
    Peng X; Gong C; Zhang W; Zhou A
    Front Oncol; 2022; 12():1091088. PubMed ID: 36727075
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advances in Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma.
    Chen Y; Hu H; Yuan X; Fan X; Zhang C
    Front Immunol; 2022; 13():896752. PubMed ID: 35757756
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Angiogenesis and immune checkpoint dual blockade: Opportunities and challenges for hepatocellular carcinoma therapy.
    Li SQ; Yang Y; Ye LS
    World J Gastroenterol; 2022 Nov; 28(42):6034-6044. PubMed ID: 36405383
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapeutic Approaches for Treating Hepatocellular Carcinoma.
    Shen W; Chen Y; Lei P; Sheldon M; Sun Y; Yao F; Ma L
    Cancers (Basel); 2022 Oct; 14(20):. PubMed ID: 36291797
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of Hepatocellular Carcinoma with Immune Checkpoint Inhibitors and Applicability of First-Line Atezolizumab/Bevacizumab in a Real-Life Setting.
    Plaz Torres MC; Lai Q; Piscaglia F; Caturelli E; Cabibbo G; Biasini E; Pelizzaro F; Marra F; Trevisani F; Giannini EG
    J Clin Med; 2021 Jul; 10(15):. PubMed ID: 34361985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Benefits of combination therapy with immune checkpoint inhibitors and predictive role of tumour mutation burden in hepatocellular carcinoma: A systematic review and meta-analysis.
    Zheng J; Shao M; Yang W; Ren J; Chen X; Yang H
    Int Immunopharmacol; 2022 Nov; 112():109244. PubMed ID: 36126410
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune-Based Combination Therapies for Advanced Hepatocellular Carcinoma.
    Carloni R; Sabbioni S; Rizzo A; Ricci AD; Palloni A; Petrarota C; Cusmai A; Tavolari S; Gadaleta-Caldarola G; Brandi G
    J Hepatocell Carcinoma; 2023; 10():1445-1463. PubMed ID: 37701562
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Treatment Landscape of Advanced Hepatocellular Carcinoma.
    Wong KM; King GG; Harris WP
    Curr Oncol Rep; 2022 Jul; 24(7):917-927. PubMed ID: 35347594
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.